ClinicalTrials.gg
RecruitingNCT07864051POSSEMUpdated Oct 7, 2026

Predicting Plaque Growth Using Blood Flow Stress Markers: A Proof-of-Concept Study

An interventional study of PCCTA scan and Endothelial cell isolation from peripheral blood sample in Coronary Artery Disease (CAD), sponsored by Queen Mary University of London. Recruiting at 1 site in United Kingdom. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Queen Mary University of London · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 7, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
270
Allocation
Not applicable
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 283 studies in Coronary Artery Disease with a site in United Kingdom — 43 open to participants now, 73 under way, 6 of them phase 3. Coronary Artery Disease · United Kingdom.

Planned enrollment
85th of 190
270 · median 194
Started
2026
with 13 others
No phase
114 of 283
19 open now
Primary completion
2031-09
later than 68 of 72 live
Registered
281st of 283
by date
Lead sponsor
7 of 283
Queen Mary University of London

Among the 283 studies in Coronary Artery Disease with a site in United Kingdom, this one is the 85th largest by planned enrollment of the 190 interventional ones that give a count, is one of 14 that started in 2026, is one of 114 with no phase, reaches primary completion later than 68 of the 72 other live ones, and was the 281st registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

43 of the 283 studies in Coronary Artery Disease with a site in United Kingdom are open now. Recruiting first, the newest first:

37 more — sign in →

All 43 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 283 studies in Coronary Artery Disease with a site in United Kingdom, or all of them as a file.
02

Study summary

Coronary artery disease occurs when fatty deposits (plaques) build up inside the arteries that supply blood to the heart. Some plaques remain stable, while others continue to grow or become more likely to rupture, which can lead to a heart attack. Identifying plaques that are at higher risk of progression could help doctors provide earlier and more personalized treatment.

The purpose of this study is to determine whether combining information about blood flow within the coronary arteries with information about a person's biological response to blood flow can improve prediction of plaque growth. Participants undergoing treatment for coronary artery disease will have a specialized heart scan to assess blood flow patterns around plaques in their coronary arteries. Researchers will also collect blood samples to study cells that line blood vessels and investigate how these cells respond to blood flow forces.

The study will follow participants over time to determine whether plaques are more likely to progress in individuals who show a stronger biological response to abnormal blood flow. The findings may help researchers develop new ways to identify patients at higher risk of future heart problems and support the development of more personalized approaches to prevention and treatment of coronary artery disease.

Read the detailed description

Coronary artery disease (CAD) is caused by the build-up of atherosclerotic plaques within the coronary arteries. While some plaques remain stable, others continue to grow and may develop features associated with an increased risk of rupture, potentially leading to acute coronary events. Identifying plaques that are likely to progress remains a major challenge in cardiovascular medicine and could enable more personalized prevention and treatment strategies.

Wall shear stress (WSS), the frictional force generated by flowing blood on the vessel wall, plays an important role in vascular biology and atherosclerosis. Previous imaging studies using computational fluid dynamics (CFD) have demonstrated that regions exposed to low WSS are more likely to undergo plaque progression and adverse vascular remodelling. However, low WSS alone has limited predictive accuracy because many plaques exposed to low WSS do not progress over time. This suggests that additional biological factors influence how individual patients respond to adverse flow conditions.

Experimental studies have demonstrated substantial variation between individuals in endothelial cell responses to WSS. Endothelial cells line the inner surface of blood vessels and are key regulators of vascular health. These findings support the hypothesis that plaque progression is influenced not only by local haemodynamic conditions but also by patient-specific biological sensitivity to WSS. The POSSEM (Plaque Prediction Obtained with Shear Stress Endothelial Metrics) study aims to evaluate whether combining local WSS measurements with patient-specific endothelial responses improves prediction of plaque progression compared with assessment of WSS alone.

POSSEM is a prospective, longitudinal interventional study enrolling patients with established CAD who are undergoing coronary revascularisation. Baseline photon-counting computed tomography coronary angiography (PCCTA), performed as part of routine clinical care, will be used to reconstruct patient-specific coronary artery anatomy. Computational fluid dynamics will then be applied to these anatomical models to characterize local haemodynamic parameters, including WSS, within coronary plaques.

A peripheral blood sample will be collected from each participant. Endothelial colony-forming cells will be isolated and cultured to provide a patient-specific assessment of endothelial responsiveness to WSS. In laboratory experiments, these cells will be exposed to flow conditions and analysed for molecular markers associated with endothelial activation, inflammation, and cellular stress responses. These analyses will be used to quantify each participant's biological sensitivity to WSS.

Participants will undergo repeat PCCTA imaging approximately 12 months after the baseline assessment, hence, interventional study. Changes in plaque burden and plaque characteristics between baseline and follow-up scans will be evaluated and related to both local WSS measurements and endothelial responsiveness. The study will investigate whether plaques located in regions of low WSS are more likely to progress in patients demonstrating heightened biological responses to WSS compared with those exhibiting lower responsiveness.

Coronary CT datasets will undergo detailed plaque characterization and three-dimensional vessel reconstruction. CFD modelling will be used to estimate local blood flow patterns and WSS throughout the coronary tree. Plaque morphology and composition will be assessed at baseline and follow-up, enabling assessment of disease progression over time. Endothelial cell studies will be performed using standardized laboratory methods to measure flow-responsive biological pathways.

The study is intended as a proof-of-principle investigation of a combined haemodynamic and biological approach to risk prediction. The use of cultured endothelial cells is a research tool designed to establish whether individual responses to WSS contribute to plaque progression. Although this approach is not expected to be used routinely in clinical practice, the findings may support the future development of simpler blood-based biomarkers capable of identifying patients with heightened sensitivity to adverse flow conditions.

Study participation involves collection of a peripheral blood sample and an additional follow-up PCCTA scan. The repeat PCCTA exposes participants to a small additional dose of ionising radiation and requires administration of iodinated contrast material. Appropriate measures will be taken to minimise these risks, including exclusion of individuals with significant renal impairment or known contrast allergy and the use of standard dose-optimised imaging protocols.

This study seeks to improve understanding of the interaction between coronary blood flow and patient-specific vascular biology in atherosclerosis. By integrating haemodynamic and biological information, the study aims to establish whether a combined WSS-biological signature can improve prediction of coronary plaque progression and inform future strategies for personalized cardiovascular risk assessment.

03

Conditions studied

  • Coronary Artery Disease (CAD)

Keywords

  • Coronary Artery Disease
  • Endothelial cell
  • Wall shear stress
  • Computational fluid dynamics
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥40
  2. Stable angina, defined as typical symptoms with evidence of reversible ischemia in non-invasive test and/or documented obstructive coronary artery disease on coronary angiography (>70% stenosis of at least one major epicardial coronary artery or positive fractional flow reserve study)
  3. Patient that is willing and can provide written .

Exclusion criteria

Exclusion Criteria:

  1. Acute coronary syndrome within \<3 months
  2. Estimated (eGFR) \<60ml/min/1.73m²
  3. Previous coronary artery bypass surgery
  4. Decompensated heart failure, or ≤30%
  5. Patient allergic to contrast or cannot receive treatment with aspirin, heparin, or thienopyridines
  6. Anticipated \<2 years
  7. Flow limiting coronary artery disease in the proximal segments of all the 3 epicardial coronaries
  8. History of heart transplantation
  9. Patient that requires surgical revascularization
  10. Extensive coronary artery disease (i.e., multiple chronic total occlusions) or tortuous coronary anatomy that does not allow assessment of the coronary arteries with intravascular imaging
  11. Pregnant women will be excluded. All women of will undergo a pregnancy risk assessment and a urine pregnancy test prior to the 12-month PCCTA scan, in line with standard clinical practice for all PCCTA scans.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
270 participants (estimated)

Study arms

  • Other
    Single arm

    Procedure: PCCTA scan · Other: Endothelial cell isolation from peripheral blood sample

Interventions

  • ProcedurePCCTA scan

    During the scans, the patient will be cardiac monitored using ECG synchronisation. PCCTA scan acquisition and parameters will follow Barts Health's standard operating procedures and institutional protocols.

    Also known as: Naeotom Alpha scanner

  • OtherEndothelial cell isolation from peripheral blood sample

    A 50mL blood sample will be collected from consenting patients. The blood will be processed to isolate peripheral mononuclear cells. These cells will be cultured to support the growth of endothelial colony forming cells (ECFCs).

06

What researchers measure

Primary outcomes

  1. Percentage change in plaque burden over 12 months

    Percentage change in plaque burden over 12 months, analysed using linear regression with response to WSS as a continuous predictor

    Time frame: From the first CT scan to the second CT scan- 12 months apart

  2. ECFC isolation from peripheral blood sample

    Peripheral blood will be drawn at the point of recruitment. Blood will be processed to culture endothelial colony forming cells (ECFCs).

    Time frame: The process takes around 4 weeks after blood draw

07

Study locations

1 of 1 sites recruiting
  • Queen Marys University London
    London, EC1M 6EU, United Kingdom
    Recruiting
    • Paul C Evans · Contactpaul.evans@qmul.ac.uk · +447825611695
    • Paul C Evans, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Sep 2031, 59 months after the start.

Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 59 months is above that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2026
First posted
Oct 7, 2026
StartActual
Sep 17, 2026
Primary completionEst.
Sep 1, 2031
CompletionEst.
Sep 17, 2031
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07864051
Responsible party
Sponsor
First posted
Oct 7, 2026
Start date
Sep 17, 2026
Primary completion
Sep 1, 2031 (estimated)
Completion
Sep 17, 2031 (estimated)
Last update
Oct 7, 2026

Study contacts

Paul C Evans
Contact
paul.evans@qmul.ac.uk
+447825611695

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion